18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

Biyun Wang, MD

Status: Completed

Conditions: HER2-positive Breast Cancer

Treatments: Drug: Pyrotinib

Study type: Observational

Funder types: Other

Identifiers

NCT04756921

YOUNGBC-13

Details and patient eligibility

About

Heterogeneity of 18F-fluorodeoxyglucose (FDG) uptake is a promising marker for predicting response to treatment. This study aimed to evaluate the ability of pretreatment positron emission tomography/computed tomography (PET/CT) 18F-FDG-based heterogeneity to predict the response to pyrotinib in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).

Enrollment: 30 patients

Sex: Female

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pathologically confirmed HER2 positive breast cancer
• Treated with Pyrotinib in the metastatic settings
• Underwent whole-body FDG PET/CT within 4 weeks before the initiation of pyrotinib and capecitabine were included in this study

Exclusion criteria

• Incomplete medical history
• Loss of follow up

Trial design

30 participants in 1 patient group

Patients cohort

Description:

Patients with HER2 positive MBC in the Fudan University Shanghai Cancer Center who underwent whole-body 18F-FDG PET/CT before the initiation of pyrotinib was included.

Treatment:

Drug: Pyrotinib